Skip to contentB
Bio-Rad Laboratories, Inc.
B
BIOBio-Rad Laboratories, Inc. Q4 2023 · 10-K
Revenue$681.12M$681.12Mderived−6.7% vs Q4 2022 Net Income$349.70M$349.70M−57.8% vs Q4 2022 EPS Diluted$12.14$12.14−56.3% vs Q4 2022 The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Bio-Rad Laboratories, Inc. · CIK 12208 · Engraved from SEC EDGAR
−7.8%
Operating Incomederived$95,321,000−19.7% Operating Cash Flowderived$81,004,000+1.8% Free Cash Flowderived$38,739,000−13.5% Margins · derivedGross margin53.8%−0.6 pt vs Q4 2022
Operating margin14.0%−2.3 pt vs Q4 2022
Net margin51.3%−62.0 pt vs Q4 2022
ended Dec 31, 2023 · filed Feb 16, 2024 · 47 d after period end